Latest on Drug Hunter
-
Merck’s Oral PCSK9 Inhibitor and Nurix’s BTK Degrader Among ACS First Disclosures
12 mins read •
4 days ago
Merck’s Oral PCSK9 Inhibitor and Nurix’s BTK Degrader Among ACS First Disclosures
The First Disclosures section of the 2023 ACS Spring Meeting in Indianapolis, organized by GSK’s Nikki Goodwin, covers three…
12 mins read
Top Premium Articles
-
Merck’s Oral PCSK9 Inhibitor and Nurix’s BTK Degrader Among ACS First Disclosures
12 mins read •
4 days ago
Why Did GSK Pay $1.9B for Momelotinib, an Oral Ph. III Myelofibrosis Candidate?
6 mins read •
11 months ago
Join the Drug Hunter mailing list
to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.
Molecules of the Month
Drug Discovery Resources
- Drug Discovery Resources
- Drug Discovery Posters and Cheat Sheets
- Drug Discovery IPOs and Industry Reviews
- Lists of Approved Drugs
- Classics in Drug Discovery
- Drug Discovery Books
- Drug Discovery Conferences
- What is a Drug Hunter?
- Topliss Tree and Topliss Scheme Posters
- PK Reference Table / Cheat Sheet
- Pd-Couplings Table / Cheat Sheet
molecule of the day
Remibrutinib – March
Molecules
Molecules of the Month
2023202220212020Featured Reviewers
Join the Drug Hunter mailing list
to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.
Join Subscribers from
…and hundreds more!
Search By Structure
